Transaction in Own Shares

Summary by AI BETAClose X

Hikma Pharmaceuticals Plc has announced share repurchases totaling 73,836 ordinary shares between June 29 and July 3, 2026, as part of its $250 million buyback program. These shares were acquired on XLON at prices ranging from 1,504.00 to 1,562.00 pence, with a volume-weighted average price of 1,545.77 pence for the July 3 purchases. The company intends to cancel these repurchased shares, and since the program's inception on February 26, 2026, Hikma has bought back 9,740,013 shares for a total cost of £131,960,730.15, leaving 212,146,440 ordinary shares in issue.

Disclaimer*

UK 100

Latest directors dealings